AnaptysBio

ANAB · NASDAQ

$45.43−$3.81 (−7.74%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $49.24

ANAB analyst rating

BuyConsensus of 13 analysts over the last 12 months. 92% rate it a buy.

Strong buy0
Buy12
Hold1
Underperform0
Sell0

12-month price target · 11 analysts

Average $91.67 (+101.8% upside)

Low: $75.75
Now: $45.43
High: $147.00

Upgrades and downgrades

The latest rating actions, newest first

ANAB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Sep 30, 2026	Maintains	Overweight	$70.00 → $60.00	48%
HC Wainwright & Co.	Sep 24, 2026	Maintains	Buy	$95.00	40%
Leerink Partners	Sep 23, 2026	Maintains	Outperform	$90.00 → $81.00	71%
TD Cowen	Aug 25, 2026	Maintains	Buy	$75.00 → $70.00	27%
HC Wainwright & Co.	Aug 24, 2026	Maintains	Buy	$95.00	40%
HC Wainwright & Co.	Jun 10, 2026	Initiates	Buy	$95.00	40%
UBS	May 13, 2026	Maintains	Buy	$60.00 → $76.00	53%
Barclays	May 13, 2026	Maintains	Overweight	$63.00 → $75.00	46%
Piper Sandler	May 4, 2026	Maintains	Overweight	$95.00 → $93.00	37%
Leerink Partners	Apr 28, 2026	Maintains	Outperform	$66.00 → $85.00	71%

The case for and against

Updated Oct 21, 2026

Bull case

AnaptysBio is attractive because its value is increasingly anchored by Jemperli, whose global net sales reached $331M in 2Q26 and $644M in 1H26, rising 26% and 34% year over year, respectively. The company benefits from multiple near-term catalysts, including Health Canada’s review acceptance for rectal cancer, FDA priority review with a February 2027 PDUFA, and a December 12, 2026 PDUFA for Quimilza, while AZUR-1 data showed meaningful and sustained complete responses at 12 months. Longer term, expanding Jemperli into colorectal cancer and other tumor types, plus patent life through 2035 to 2037, supports durable royalty growth and potential annualized royalties above $390M as early as 2029.

Bear case

AnaptysBio is exposed to substantial fundamental risk because its value depends on uncertain clinical outcomes, regulatory approvals, and partner-driven royalty streams rather than an established commercial base. The company faces multiple overhangs, including failed or inconclusive Jemperli trials, ongoing litigation with GSK, and regulatory risk around both Jemperli expansion and the submitted BLA for imsidolimab, any of which could reduce royalty upside and overall valuation. Although it currently does not project a need for additional capital, disappointing financial results, slower Jemperli uptake, or heightened PD-1/PD-L1 competition could pressure cash needs and sentiment in a capital-intensive biotech model.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.